AKT1 and lung cancer: In lung cancer, abnormal activation of the PI3K/Akt pathway can cause healthy cells to become cancerous, leading to increased cancer cell growth, decreased sensitivity to radiation and chemotherapy, and the development of drug resistance (Rascio et al., 2021; He et al., 2021).